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Cidofovir (CDV) is a highly effective inhibitor of orthopoxvirus replication and may be used intravenously to treat smallpox or
complications arising from the smallpox vaccine under an investigational new drug application (IND). However, CDV is absorbed poorly
following oral administration and is inactive orally. To improve the bioavailability of CDV, others synthesized alkoxyalkanol esters of CDV
and observed >100-fold more activity than unmodified CDV against cowpox, vaccinia, and variola virus (VARV) replication. These ether
lipid analogs of CDV have high oral bioavailability in mice. In this study, we compared the oral activity of CDV with the
hexadecyloxypropyl (HDP)-, octadecyloxyethyl-, oleyloxypropyl-, and oleyloxyethyl-esters of CDV in a lethal, aerosol ectromelia virus
(ECTV) challenge model in A/NCR mice. Octadecyloxyethyl-CDVappeared to be the most potent CDVanalog as a dose regimen of 5 mg/kg
started 4 h following challenge completely blocked virus replication in spleen and liver, and protected 100% of A/NCR mice, although oral,
unmodified CDV was inactive. These results suggest that this family of compounds deserves further evaluation as poxvirus antiviral.
D 2003 Elsevier Inc. All rights reserved.Keywords: Ether lipid; Cidofovir; MousepoxIntroduction
With the heightened potential for bioterrorism, there is a
need for an efficacious antiviral for the treatment of small-
pox or human monkeypox and the complications that arise
from the smallpox vaccine. Cidofovir (CDV) is effective
against a wide-range of DNA virus and retrovirus infections
probably by interfering with viral DNA synthesis (De
Clercq, 1998). CDV was first shown active in vitro against
vaccinia virus (VACV) by De Clercq et al. (1987), although
others demonstrated 50% effective concentration (EC50)
values in the 10–50 AM range against several other ortho-
poxviruses including variola virus (VARV), monkeypox
virus, and cowpox virus (CPXV) (Baker et al., 2003; Kern,
2003). Furthermore, parenterally administered CDV was
active against lethal VACV and CPXV infections in mice
(Bray et al., 2000; Neyts and De Clercq, 1993; Smee et al.,
2001), but was poorly absorbed when administered orally0042-6822/$ - see front matter D 2003 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2003.11.015
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E-mail address: bullerrm@slu.edu (R.M. Buller).(Wachsman et al., 1996). Oral bioavailability is a desirable
property of drugs proposed for emergency use in an out-
break of smallpox or monkeypox. Previous studies by
Hostetler et al. (1997) showed that derivatization of acyclo-
vir with 1-O-hexadecyl-glycero-3-phosphate provided a
compound that was 100% orally bioavailable in mice. Using
this approach, several ether lipid esters of CDV and cyclic
CDV were synthesized and tested in vitro against VACVand
CPXV (Kern et al., 2002). The hexadecyloxypropyl (HDP)-
and octadecyloxyethyl (ODE)-esters of CDV had EC50
values of 0.2–1.1 and 0.1–0.4 AM, respectively, against
five strains of VACV versus 10.1–46.2 AM for CDV;
however, no in vivo experiments have yet been reported.
In this study, we evaluate the antiviral activity of this class
of compounds in vitro and in vivo against a natural mouse
pathogen, ectromelia virus (ECTV), the causative agent of
mousepox (Buller and Palumbo, 1991).
Natural infections with ECTVoccur through microscopic
abrasions, which allow access of the virus to the epidermal
or dermal layers of the cornified mouse skin. ECTV
replicates locally at the site of infection, and reaches internal
organs via the afferent lymphatics, draining lymph node,
Table 1
IC50 values of cidofovir and ether lipid esters against ectromelia virus




CDV 12 F 2.8 12 40
HDP-CDV 0.5 F 0.1 0.2 0.7
ODE-CDV 0.2 F 0.0 0.2 0.4
OLE-CDV 0.2 0.2 NAc
OLP-CDV 1.1 F 0.2 NA 1.1 F 0.0
a Plaque reduction assay in CV-1 cells.
b An ECTVrecombinant expressingmurine IL-4 from the 7.5 early promoter.
c No IC50 value available.
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major organs, especially spleen and liver, results in detec-
tion of virus in blood by 4 or 5 days p.i. (secondary
viremia). Virus replication in skin produces the typical
exanthem, which can be seen as early as 6 days p.i., and
is dependent on the mouse strain. Virus is transmitted from
the primary and secondary lesions. With the A/NCR strain
of mouse used in this study, death is observed 7–10 days
p.i. before the development of an exanthem, and is a
consequence of extensive liver necrosis. The mousepox
model differs from smallpox in the short course of disease,
and severe pulmonary pneumonia associated with local
replication following an aerosol infection. The major ad-
vantage of using ECTV for the evaluation of antiviral
compounds lies in its severe disease course in adult,
immunocompetent mice, which results in uniform mortality
and LD50 values of less than 1 plaque forming unit (PFU)
by the footpad route of infection (Buller and Palumbo,
1991; Chen et al., 1992).Results
In vitro sensitivity of ectromelia virus to alkoxyalkyl esters
of cidofovir
A series of analogs of CDV were synthesized having
alkoxyalkanols of varying structure as shown in Fig. 1.
(Beadle et al., 2002). As a first step in testing these
compounds in an ECTV mouse model, we determined their
EC50 values in a CV-1 cell plaque reduction assay with
VACV strain WR (VACV-WR), ECTV, and a second pool
of ECTV prepared with an ECTV recombinant expressing
murine IL-4. VACV-WR was included as its sensitivity to
CDV and analogs had previously been reported. The EC50Fig. 1. Structure of cidofovirfor HDP-CDV, ODE-CDV, oleyloxyethyl-CDV (OLE-
CDV), and oleyloxypropyl-CDV (OLP-CDV) against the
two distinct pools of ECTV were 0.2–1.1 AM, which
represented an 11- and 60-fold enhanced antiviral activity
as compared to CDV (Table 1). The tested compounds had
similar EC50 values against ECTV and VACV-WR.
Efficacy of four alkoxyalkyl esters of cidofovir in an
ectromelia virus aerosol challenge model
Because ECTV has an LD50 of less than 1 PFU in the A/
NCR strain of mouse following footpad inoculation, this
strain was chosen to evaluate the efficacy of CDV analogs
(Chen et al., 1992). Preliminary experiments demonstrated
that adult A/NCR mice were also highly sensitive by the
aerosol route. Doses of 20000, 1000, 63, and 6 PFU per
mouse gave mean time to death (MTD) values of 8.1, 9.3,
10.2, and 14 days, respectively. The calculated LD50 value
was 32 PFU. For comparison, the commonly used CPXV
mouse model required an aerosol exposure dose of 5  106
PFU of CPXV to obtain 100% mortality withf3-week-oldand ether lipid esters.
R.M. Buller et al. / Virology476BALB/c mice, and lowering the exposure dose to 5  104
PFU caused only transient, mild illness, and weight loss, but
no deaths (Bray et al., 2000). Thus, the ECTVaerosol model
provides a much greater dynamic range for evaluating
antivirals. One can choose a low lethal dose of 100 PFU,
which is approximately threefold greater than the LD50 or
use a high dose of 1000–10000 times the LD50 to fully test
the robustness of the antiviral.
The goal of our initial in vivo assessment was to select
the two best compounds for a more in depth analysis. A 3
mg/kg dose was chosen for the evaluation as preliminary
studies suggested this dose would permit discrimination
among the activities of closely related compounds. This
drug dose was not toxic as the maximal tolerated dose for
HDP-CDV was >30 mg/kg and >10 mg/kg for ODE-, OLP-,
and OLE-CDV when administered as five consecutive daily
doses to uninfected mice. A/NCR mice were treated by
gavage with 3 mg/kg of test compounds, exposed to an
aerosol dose of 1.7  105 PFU of ECTV, and were
monitored for mortality, day of death, and lung, spleen,
and liver infectivity levels (Table 2). As expected from its
low bioavailability, CDV failed to protect any mice from a
lethal infection, and gave the shortest MTD (9.8F 3.5 days)
of any of the compounds. ODE-CDV showed the greatest
promise among the tested compounds as only 10% of the
treated mice died following aerosol challenge, significantly
lower virus titers were detected in spleen tissue as compared
to the other compounds, and no detectable virus infectivity
was found in liver tissue. Careful examination of the
survival percentages, MTD values, and virus titers in tissues
indicated that HDP-CDV, OLP-CDV, and OLE-CDV had
similar activities. Because the double bond contained in the
lipid moiety of OLP-CDV and OLE-CDV could potentially
affect long-term drug stability, and because these com-
pounds were not demonstrably better than HDP-CDV, we
chose not to study them further in vivo.Table 2
Effect of oral gavage treatment with cidofovir and alkoxyalkyl esters on an infec
Druga Day of death Mortality at 21 days V
mean F SD post-aerosol challenge S
CDV 9.8F3.5 11/11 (100%) 1.
HDP-CDV 12.8F1.3*** 8/11 (72%) 2.
ODE-CDVd NAe*** 1/10 (10%)*** 6.
OLP-CDV 14.4F4.4*** 9/11 (81%) 7.
OLE-CDVf 13.4F3.4*** 6/11 (54%)** 2.
Control 6.3F0.4 11/11 (100%) 5.
Arithmetic means and standard deviations from the mean are provided. Statistical
0.01, and P < 0.001, respectively.
a Mice were treated daily with 3 mg/kg of drug by gavage on days 0–4. Infectio
aerosol dose was 1.7  105 PFU.
b Five mice from each treatment group were sacrificed at 7 days post-aerosol ch
infectivity.
c The value in ( ) indicates the number of samples in which infectivity was below
d Only three mice were available for necropsy.
e Not applicable.
f Only two mice were available for necropsy.Dose response evaluation of HDP-CDV and ODE-CDV in
an ectromelia virus aerosol challenge model
Groups of A/NCR mice were treated by gavage with 10,
5, 2.5, or 1.25 mg/kg of CDV, HDP-CDV, or ODE-CDV,
exposed to an aerosol dose of 2.3  104 PFU of ECTV, and
monitored for mortality, day of death, and lung, spleen, and
liver infectivity levels (Fig. 2). As expected, oral CDV
failed to provide any protection against a lethal ECTV
infection over the range of doses tested. ODE-CDV was
clearly more potent than HDP-CDV for protection against a
lethal aerosol ECTV challenge as it protected more mice
against death at the lower doses (5, 2.5, and 1.25 mg/kg),
and also extended the MTD values (Fig. 2, Panel A). Virus
titers in lung tissue of HDP-CDV and ODE-CDV-treated
mice were similar at all tested doses, and only differed
significantly from phosphate-buffered saline or CDV-treated
mice at the 10 mg/kg dose (Fig. 2, panel B). Virus titers in
spleen tissue of HDP-CDV and ODE-CDV-treated mice
differed significantly from phosphate buffered saline or
CDV-treated mice at all tested doses (Fig. 2, panel C).
Although the mean virus titers in spleen tissue of HDP-CDV
and ODE-CDV-treated mice were similar at doses of 1.25
and 2.5 mg/kg, three ODE-treated mice lacked detectable
virus infectivity as compared to none for the HDP-CDV-
treated mice. The greatest difference in tissue virus infec-
tivity between HDP-CDV and ODE-CDV-treated mice was
observed in the liver, which shows severe pathology in fatal
cases of mousepox (Buller and Palumbo, 1991). At the
lowest drug dose employed (1.25 mg/kg), virus titers in liver
were almost 100-fold lower in ODE-CDV-treated mice as
compared to the HDP-CDV treatment group (Fig. 2, panel
D). In addition, two ODE-CDV-treated mice lacked detect-
able virus infectivity. The apparent difference in liver titers
between HDP-CDV and ODE-CDV-treated mice at 2.5 mg/
kg is not considered significant as each data point contained
318 (2004) 474–481tion induced in mice by aerosolized ectromelia virus
irus infectivity (PFU/ml F SD)b
pleen Liver Lung
1  107 F 1.5 1.2  107 F 1.6 3.8  106 F 1.0
0  105 F 2.4 3.3  104 F 2.9 (2)c 2.0  105 F 1.7
4  103 (2) <1  102 (3) 1.6  105 F 1.0
8  105 F15 1.3  104 F 2.1 (1) 5.0  105 F 4.7
1  106 F 2.6 2.3  105 F 3.2 2.4  105 F 3.3
0  106 F 1.0 9.6  106 F 14 3.0  105 F 2.4
significance from control was indicated by *, **, and *** for P < 0.05, P <
n by aerosol occurred f4 h before the first drug treatment. The presented
allenge. Lung, spleen, and liver tissues were isolated and tested for virus
the limit of defection (<102).
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lacking detectable virus infectivity. When surviving animals
were sacrificed at 21 days postinfection at the completion of
the experiment, no residual virus infectivity was detected in
spleens and livers (data not shown).Discussion
CDV (Vistide) is licensed for intravenous use in the
treatment of human cytomegalovirus retinitis (HCMV) in
HIV-infected patients, and is the subject of a treatment
investigational new drug application (IND) for smallpox
and complications arising from the smallpox vaccine. It also
has broad spectrum antiviral activity against a wide-range of
DNA virus and retrovirus infections, but oral bioavailabilityFig. 2. Dose response evaluation of HDP-CDV and ODE-CDV in an ectromelia
gavage with the indicated doses of CDV (n), HDP-CDV (), or ODE-CDV (E) on
of 2.3  104 PFU/mouse, which was givenf4 h before the first drug treatment. E
given with its MTD unless no deaths were observed. Five mice from each treatme
liver (D) tissues were isolated, and virus infectivity measured. Arithmetic means an
the limit of detection in each treatment group. Each tissue sample, which lacked d
panel. At all treatment doses, the percentage of surviving HDP-CDVand ODE-CD
and at the 1.25 mg/kg dose, the percentage of surviving ODE-CDV-treated mice w
panel B, virus titers in lungs of HDP-CDV and ODE-CDV-treated mice differed s
0.05). In panel D, virus titers in liver of ODE-CDV-treated mice differed significan
( P < 0.05).of <5% hinders its development as an efficacious oral
antiviral drug (De Clercq, 1998; Wachsman et al., 1996).
Oral bioavailability can be significantly enhanced by deriv-
atization of CDV with ether lipid residues of various chain
lengths (Ciesla et al., 2003). Radioactive versions of HDP-,
ODE-, and OLP-CDVorally administered to mice achieved
plasma bioavailability levels of 88–97%, and concentra-
tions of 1.4–3.4 AM (Ciesla et al., 2003). This enhanced
bioavailability appeared because of the general resemblance
of alkoxyalkyl esters of CDV to a naturally occurring
compound, lysophosphatidylcholine, most of which is
absorbed intact from the small intestine (Scow et al.,
1967). Unexpectedly, the alkoxyalkyl esters of CDV also
showed a dramatic decrease in the EC50 values against
VACV, CPXV, and HCMV (Beadle et al., 2002; Kern et
al., 2002). Using VACV-WR in human foreskin fibroblasts,virus aerosol challenge model. Groups of 16 A/NCR mice were treated by
days 0–4. Mice were exposed to a small particle aerosol presenting a dose
leven mice were observed for mortality and MTD (A). Each plotted value is
nt group were sacrificed at 7 days post-challenge, lung (B), spleen (C), and
d standard deviation from the means were calculated for PFU/ml titers above
etectable virus (<102 PFU/ml), is represented below the dashed line in each
V-treated mice differed significantly from that of the CDV treatment group,
as significantly different from the HDP-CDV treatment group ( P < 0.05). In
ignificantly from the CDV treatment group only at the 10 mg/kg dose ( P <
tly from that of the HDP-CDV treatment group only at the 1.25 mg/kg dose
Fig. 2 (continued).
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ODE-CDV of 1.1 F 1.0 and 0.2 F 0.2 AM, respectively,
which compared favorably with the values summarized in
Table 1 (HDP-CDV, 0.5 F 0.1 AM, and ODE-CDV, 0.2 F
0.0 AM). Importantly, the Kern et al. (2002) study deter-
mined the selectivity indices (SI) of HDP-CDV and ODE-
CDV to be 6- and 11-fold, respectively, greater than CDV
using CPXV and VACV. The SI value relates the toxicity
and efficacy of a compound by dividing the drug’s 50%
cytotoxic concentration by the 50% effective concentration.
As compared to CDV, the larger SI values for analogs HDP-
CDV and ODE-CDV indicate that these compound are
excellent candidates for in vivo efficacy testing.
This marked increase in antiviral activity in vitro was due
to greatly increased cellular uptake of HDP-CDV relative to
CDV. Intracellular levels of the activated antiviral com-
pound, CDV-diphosphate, were 100 times greater after
exposure of cells to HDP-CDV than CDV (Aldern et al.,
2003). Furthermore, the intracellular half-life for CDV-DPwas 10 and <2.7 days following exposure of cells to HDP-
CDV and CDV, respectively (Aduma et al., 1995; Aldern et
al., 2003). The efficient uptake into cells of alkoxyalkyl
esters of CDV such as HDP-CDV is thought to occur via
rapid association with cellular membrane phospholipids,
whereas the uptake of CDV is slow, and has been shown
to occur by fluid phase endocytosis (Connelly et al., 1993).
Although this increased cellular uptake of alkoxyalkyl esters
of CDV was associated with increased toxicity, the SI index
was still significantly better than CDV (Kern et al., 2002).
Furthermore, CDV is highly concentrated in the kidney and
its dose-limiting toxicity is renal; however, the peak kidney
levels of HDP-CDV and ODE-CDV are only 3.3% of CDV
(Ciesla et al., 2003). Thus, this class of CDV analogs is
worthy of further investigation as possible oral therapies for
diseases caused by viruses including HCMV, herpes simplex
viruses, and poxviruses.
In this study, we investigated the efficacy of alkox-
yalkyl esters of CDV in a mouse model for smallpox. We
R.M. Buller et al. / Virology 318 (2004) 474–481 479compared the oral activity of CDV and CDV analogs in
an aerosol ECTV challenge model in A/NCR mice. ODE-
CDV appeared to be the most potent CDV analog as a 5
mg/kg, five dose regimen protected 100% of A/NCR
mice from a lethal aerosol challenge dose of f1000
times the LD50. Significant protection was also observed
at 1.25 mg/kg dose. Virus replication in spleen and liver
was not detected when mice were treated with oral doses
of ODE-CDV at 5 mg/kg or greater; however, virus titers
in lung tissue were reduced from control only when the
dose was at least 10 mg/kg. The relative level of virus
infectivity in tissues did not strongly correlate with drug
tissue concentration. Peak HDP-CDV and ODE-CDV
concentrations, respectively, were 1.00 and 1.19 nmol/g
in lung, 0.56 and 0.79 nmol/g in spleen, and 43.7 and
25.7 nmol/g in liver (Ciesla et al., 2003). The high levels
of HDP-CDV and ODE-CDV in liver tissue may favor
antiviral efficacy against ECTV as compared to VACV
and VARV because ECTV replicates to far higher levels
in liver tissue than does VACV or VARV. The synthesis
of an alkoxyalkyl ester of CDV that exerts greater
antiviral activity in lung tissue than ODE-CDV, or the
administration of aerosolized CDV, may reduce ECTV
virus replication in the lung following an aerosolized
challenge (Bray et al., 2002; Smee et al., 2000). A
strategy of adjusting the character of the lipophilic adduct
to increase the concentration of lung CDV-diphosphate is
based on the observation that 14C-labeled ODE-CDV
given orally provides substantially higher drug concentra-
tion in lung tissue than the slightly less lipophilic HDP-
CDV (Ciesla et al., 2003). These approaches may not be
necessary, however, as pulmonary disease and presumably
extensive variola virus replication in lung was not an
early finding in smallpox, rather bronchopneumonia when
observed was usually associated with late stage disease
(Fenner et al., 1988). A strategy to optimize the pharma-
cokinetics of alkoxyalkyl esters of CDV would be depen-
dent on a thorough understanding of the pathogenesis of
smallpox. This knowledge is currently lacking. The
results presented here suggest that the ODE-CDV and
similar compounds should be further examined in oral
dose optimization and therapeutic intervention studies as
potential antivirals against human orthopoxvirus systemic
disease caused by VACV, monkeypox virus, and VARV.Materials and methods
Cells and virus
BS-C-1 cells (ATCC CCL 26) were grown in Dulbec-
co’s modified Eagle’s medium (DMEM) containing 10%
bovine serum fetal clone III (Hyclone, Logan, UT), 2
mM L-glutamine (GIBCO, Grand Island, NY), 100 U/ml
penicillin (GIBCO), and 100 Ag/ml streptomycin
(GIBCO). A plaque-purified isolate of the MOS strainof ECTV (ATCC VR-1374) designated MOS-3-P2 was
propagated in an African green monkey kidney cell line,
BS-C-1 (Chen et al., 1992). Virus was purified through a
sucrose cushion as described elsewhere (Moss and Earl,
1998). The VACV-WR (ATCC VR-119) was propagated
as described elsewhere (Moss and Earl, 1998). Virus
infectivity was estimated as described previously (Wallace
and Buller, 1985). Briefly, virus suspensions were serially
diluted in PBS +1% sera, absorbed to monolayers for 1
h at 37 jC, and overlayed with a suspension of 1%
carboxyl methyl cellulose in DMEM +5% Fetal clone III.
After 4 days at 37 jC, virus plaques were visualized and
virus inactivated by the addition to each well of 0.5 ml
of a 0.3% crystal violet/10% formalin solution.
Animals
Four- to six-week-old female A/NCR mice were obtained
from the National Cancer Institute, Frederick Md., housed in
filter-top microisolator cages and fed commercial mouse
chow and water ad libitum. The mice were housed in an
animal biosafety level 3 containment area. Animal husband-
ry and experimental procedures were in accordance with




pyl]cytosine, HPMPC, Vistide) was purchased from a retail
pharmacy or was provided by Gilead Sciences, Inc. (Foster
City, CA). Ether lipid analogs of CDV (HDP-CDV, ODE-
CDV, and OLP-CDV) were prepared as described previous-
ly (Beadle et al., 2002). CDV and analogs were prepared
fresh for each experiment by dissolving the compounds in
sterile, distilled water. Solutions were stored at 4 jC over
the course of the experiment.
Plaque reduction assay
CV-1 cells were plated in wells of a 24-well cluster
plate. Each monolayer was infected with f75 plaque
forming units (PFU) of indicator virus in 0.1 ml of DMEM
+5% Fetal clone III for 60 min at 37 jC. Media was
removed by aspiration and standard virus overlay media
containing no drug or the test drug at concentrations
ranging from 0.05 to 50 AM was added. The plates were
incubated at 37 jC for 3–4 days for ECTV and 2 days for
VACV-WR, monolayers were stained, and plaques counted
using a stereomicroscope. The EC50 concentration for each
drug was calculated.
In vivo drug evaluation
Mice were exposed to aerosolized ECTV suspended in
MEM using a nose-only inhalation exposure system
R.M. Buller et al. / Virology 318 (2004) 474–481480(NOIES; CH Technologies) equipped with a 1-jet BioAer-
osol Nebulizing Generator, and operated within a class II
biological safety cabinet. The NOIES was operated with a
primary air pressure of 20 psi giving 1.5 l/min flow rate to
the aerosol chamber (without secondary air), a virus
suspension flow rate of 0.5 ml/min, and a system operating
pressure approximately 0.5 in of vacuum relative to the
outside atmospheric pressure. The NOIES delivered a
predicted median particle diameter of 0.54 F 1.2 Am
(Dr. Chad Roy, personal communication). The quantity
of virus delivered to the mice over the course of exposure
was not measured directly, but estimated by multiplying
the concentration of virus in the aerosol (CA) in PFU by
the total volume (VM) of air respired by a mouse of given
body weight over the exposure time using Guyton’s
formula for minute volumes administered to rodents (Guy-
ton, 1947). This presented virus dose is likely an upper
limit as it assumes that the virus was optimally aerosolized
and completely taken up on inhalation. Four hours follow-
ing aerosol exposure to ECTV, groups of 16 mice were
treated by gavage with 0.1 ml of sterile, distilled water
alone or water containing the test compound. This treat-
ment was repeated on days 1, 2, 3, and 4 for a total of five
doses. Five mice from each treatment group were sacri-
ficed at 7 days post-aerosol challenge, and lung, spleen,
and liver tissues were isolated. Tissue was ground in PBS
(10%w/v), frozen, and thawed three times, and sonicated
for 20 s. Virus infectivity (PFU/ml) in tissue homogenates
was estimated by titration on BS-C1 monolayers (above).
Arithmetic means were calculated for PFU/ml values
above the limit of detection (102 PFU/ml). The remaining
11 mice were observed over 21 days for clinical signs of
disease (morbidity) and mortality. Mice showing conjunc-
tivitis, little or no movement, and marked respiratory
distress were euthanized as they were near death.
Statistical methods
Statistical significance of differences between groups in
the proportion of surviving mice was determined by the
Pearson Chi-square test. Statistical significance of differ-
ences between groups in tissue infectivity titers was deter-
mined by the Wilcoxon nonparametric analysis. P < 0.05
was considered significant.Acknowledgments
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